Status:
COMPLETED
An Analysis of the Improvement and Quality of Life Trends for UK/ROI Patients Treated With Cosentyx (Secukinumab) in a Retrospective Analysis of the BADBIR Data Source
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-99 years
Brief Summary
This was a retrospective, observational study of psoriasis patients treated with secukinumab, using secondary data from BADBIR. BADBIR is a UK/ROI pharmacovigilance registry that was initiated in 2007...
Detailed Description
The BADBIR data was current up until the 31st August 2019 for this analysis. Study period: From 1st July 2015, as secukinumab was included in BADBIR in January 2016 and patients backdated 6 months, t...
Eligibility Criteria
Inclusion
- Inclusion criteria for the biologic cohort:
- Age ≥18 years at initiation of secukinumab.
- At least one follow-up visit post-registry enrollment.
- On-label dosing of secukinumab of 300mg.
- Inclusion criteria for the PsA biologic cohort:
- Age ≥18 years at initiation of secukinumab.
- At least one follow-up visit post-registry enrollment.
- On-label dosing of secukinumab of 300mg.
- Diagnosis of PsA at baseline.
Exclusion
- \- The patient did not meet the criteria stated above.
Key Trial Info
Start Date :
December 7 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 6 2021
Estimated Enrollment :
767 Patients enrolled
Trial Details
Trial ID
NCT05368818
Start Date
December 7 2020
End Date
May 6 2021
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936-1080